Evercure Holdings Pte Ltd, Gurmit Singh Chugh, and Punita Sharma will sell some of their shares under the OFS component.
The proceeds raised from the fresh issue will be used for the payment of the debt, and some funds will be utilized for the company’s general corporate usage.
The company may also plan to raise ₹185 crore through a pre-IPO placement. If this happens, the size of the fresh issue will be reduced by ₹185 crore.
The book-running lead managers to the issue are ICICI Securities, Axis Capital, Citigroup Global Markets India, and IIFL Capital Services.
Integris Medtech was co-founded by Gurmit Singh Chugh and Punita Sharma. The company is engaged in developing, making, and selling a wide range of medical devices and solutions. Its product portfolio consists of cardiovascular devices, clinical diagnostic tools, and laboratory solutions.
As of June 30, 2025, the company sells its products to over 65 countries. Its manufacturing facility is situated in India, Germany, and the Netherlands.
In FY25, Integris Medtech generated a revenue of ₹1,959.58 crore, if compared to ₹1,582.25 crore in FY24, the company’s total income increased by 23.85%. The company also moved from a loss of ₹4.8 crore in FY24 and reported a profit of ₹70.6 crore in FY25. Its profit after tax (PAT) rose to ₹103 crore in FY25.
